DEALS: Pfizer buys Vicuron for $1.9B


Pfizer buys Vicuron for $1.9B


DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Vicuron Pharmaceuticals

$1.9B buyout

The move hands Pfizer new anti-infectives for both hospital-based and community-acquired infections.

ML Laboratories

Quadrant Technologies

£46.7 million acquisition

The buyout gives ML Laboratories a big boost in the field of inhaled medicines.

Clinical Data

Genaissance Pharmaceuticals

$56 million acquisition

The buyout provides Clinical Data -- a diagnostic company -- with a leader in molecular testing.

GNI Ltd.

Shanghai Genomics

Merger

The combination marries GNI's clinical development programs with Shanghai Genomics' contract research abilities.

Genentech

Biogen Idec

$408 million plant acquisition

Biogen Idec is selling its California manufacturing facility as Tysabri's fate remains in limbo.

Cephalon

Cell Therapeutics

Trisenox acquisition

Cephalon adds an approved drug for hematologic malignancies.

QVT Fund

Biosynexus

Acquisition

The New York hedge fund acquires a portfolio of products for the prevention and treatment of infectious diseases.

Fisher Scientific

McKesson

$60 million subsidiary buyout

Fisher Scientific is buying the Bioservices division, which manages biological specimens and clinical trial materials.

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.